About

This training path in 6 modules (total 24 hours) of highly interactive online training is designed to give an extensive overview of the pharmacovigilance activities and the related documents throughout the life cycle of a medicinal product.

We will address:

  • benefit-risk analysis
  • signal management
  • data collection process
  • consolidated documents in the different phases of the life cycle
  • structure and content of consolidated documents
  • similarities, differences and synergies among the various documents
Lecturers
Marco Anelli
Info

Marco Anelli

Medical Affairs and Pharmacovigilance consultant

Marco has a medical degree from the University of Milan, specializations in Medical Statistics and Clinical Pharmacology from the University of Pavia and an international master’s degree in health economics and pharmacoeconomics from the University of Pompeu Fabra in Barcelona, plus formal training in Data Science and Artificial Intelligence.
In the last few years, he has extensively worked in the fields of pharmacoeconomics and health technology assessment.
Marco has been a free-lance consultant in Medical Affairs and Pharmacovigilance/ Drug Safety since 2022.

Before that, he has been “Head of Pharmacovigilance and Medical Affairs Advisory Services” at ProductLife Group (PLG).
As “Deputy Chief Scientific Officer”, always at PLG, Marco has also coordinated all delivery and research projects (internal and on behalf of clients) linked to Big Data, Knowledge Management, Artificial Intelligence and Machine Learning.
Previously, Marco was R&D Director at Keypharma, an Italy-based consultancy company (later acquired by PLG), where was responsible for the oversight of all clinical and preclinical aspects of projects run internally and on behalf of clients.
Drawing on a career in the pharmaceutical industry that spans more than 30 years, Marco provides expert oversight on a wide range of R&D and Medical Affairs related activities.
Marco has participated in and supervised all stages of drug development – from formulation to Phase I-IV and pharmacovigilance.
In addition, Marco is a qualified QPPV and has prepared and overseen more than 200 non-clinical and clinical overviews and summaries.
Before joining Keypharma and PLG, Marco was Medical Affairs Director at Eurand.


Tiziana von Bruchhausen
Info

Tiziana von Bruchhausen

Principal Pharmacovigilance Writer at Boehringer Ingelheim

Tiziana von Bruchhausen, PhD specialises in pharmacovigilance writing and has gained over 10 years’ experience while working in various roles for mid-sized and large pharmaceutical companies. She is currently employed as a principal pharmacovigilance writer at Boehringer Ingelheim. Her tasks and responsibilities cover pre- and post-submission activities related to the global strategic planning and the preparation of pharmacovigilance documents with a focus on DSURs, RMPs, PSURs, and health authorities’ assessment reports.
Tiziana actively promotes the professional role of medical writers in pharmacovigilance through workshops and lectures Europe-wide and has served as a session chair at international conferences. She is an active volunteer at the European Medical Writers Association (EMWA), where she has been chairing since 2017 the Pharmacovigilance Special Interest Group Committee. She was Vice President of EMWA in 2017-2018 and President in 2018-2019.


The training path is made of 6 modules:

MODULE 1 | Pharmacovigilance Documents – Basic Concepts and Definitions for Pharmacovigilance Writing
18 September 2024 – h.01:30 pm / 05:30 pm CEST

MODULE 2 | Pharmacovigilance Documents – Focus on Signal Management and Development Safety Update Reports (DSUR)
25 September 2024 – h.01:30 pm / 05:30 pm CEST

MODULE 3 | Pharmacovigilance Documents – Focus on the Risk Management Plan (RMP)
02 September 2024 – h.01:30 pm / 05:30 pm CEST

MODULE 4-5 | Pharmacovigilance Documents – Focus on the Periodic Safety Update Report  (PSUR)
09 October 2024 – h.01:30 pm / 05:30 pm CEST
16 October 2024 – h.01:30 pm / 05:30 pm CEST

MODULE 6 | Pharmacovigilance Documents – Focus on Addendum to the Clinical Overview (AddCO) and Referrals
23 October 2024 – h. 01:30 pm / 05:30 pm CET

The modules of this training path are a series of standalone training courses. Visit each course online brochure for more information. Click here

The training path admits maximum 12 attendees.

The training path will proceed with a minimum number of participants. Should this number not be reached the registered participants will be notified one week prior to the commencement of the course.

 

Super Early Bird: € 1.995,00* (unti 30 April 2024)

Early Bird: € 2.315,00* (until 18 August 2024)

Ordinary: € 2.635,00*

Freelance – Academy – Public Administration**: € 1.615,00*

* for Italian companies: +22% VAT

** Early Bird discount not applicable to Freelance – Academy – Public Administration fee

The fee includes: tuition, organizational office assistance, teaching materials and attendance certificate that will be sent after the training via e-mail.

Registrati

Ticket not available


Roberta Alberti
Roberta Alberti
Events & Training Manager
Printable Version
Cosa saprai fare dopo il percorso formativo
Risultato atteso
Understand the main pharmacovigilance activities in the life cycle of the medicinal product
Risultato atteso
Plan and prepare DSUR, PSUR/PBRER, RMP, and AddCO, exploiting similarities and synergies among the different documents
Risultato atteso
Apply writing skills to the preparation of pharmacovigilance documents

<p>Online interactive training on Zoom platform.</p>
<p><em>LS Academy will provide the access link to the virtual platform a few days before the training.</em></p>

Online interactive training on Zoom platform.

LS Academy will provide the access link to the virtual platform a few days before the training.

<p>Online interactive training on Zoom platform.</p>
<p><em>LS Academy will provide the access link to the virtual platform a few days before the training.</em></p>